Ado-trastuzumab Emtansine Evaluated With Docetaxel, Pertuzumab for Breast Cancer

Share this content:
Ado-trastuzumab emtansine in combination with docetaxel with or without pertuzumab appeared efficacious in breast cancer.
Ado-trastuzumab emtansine in combination with docetaxel with or without pertuzumab appeared efficacious in breast cancer.

Ado-trastuzumab emtansine in combination with docetaxel with or without pertuzumab appeared efficacious in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic locally advanced or metastatic breast cancer, a study published in the journal Annals of Oncology has shown.1

Because preclinical trials demonstrated enhanced antitumor activity when ado-trastuzumab emtansine was combined with docetaxel or pertuzumab, researchers sought to assess the feasibility of ado-trastuzumab emtanasine plus docetaxel in patients with HER2-positive metastatic breast cancer and with or without pertuzumab for those with locally advanced breast cancer.

For the phase 1b/2a study, researchers enrolled 25 patients with metastatic breast cancer and 73 patients with locally advanced disease. Patients with metastatic breast cancer received ado-trastuzumab emtansine 3.6 mg/kg plus docetaxel 60 mg/m2.

Participants with locally advanced breast cancer received ado-trastuzumab emtansine 3.6 mg/kg with docetaxel 100 mg/m2 and granulocyte-colony stimulating factor (G-CSF), or plus docetaxel 75 mg/m2 and pertuzumab 420 mg (840 mg for cycle 1) with G-CSF support.

Results showed that the objective response rate was 80.0% (95% CI, 59.3 - 93.2) and median progression-free survival was 13.8 months in patients with metastatic breast cancer. In locally advanced disease, the pathologic complete response rate was 60.3% (95% CI, 48.1 - 71.5).

In terms of safety, 72% and 29% of patients with metastatic and locally advanced breast cancer, respectively, experienced grade 3 or 4 neutropenia. Nearly half of all patients required dose adjustments due to treatment-related toxicities.

RELATED: Adding Bevacizumab to Chemo Not Effective for HER2- Inflammatory Breast Cancer

Ado-trastuzumab emtansine is an antibody-drug conjugate consisting of trastuzumab, a monoclonal antibody frequently used for HER2-positive cancers, linked with DM1, a cytotoxic agent. It is indicated as a single-agent for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane.

Reference

  1. Martin M, Fumoleau P, Dewar JA, et al. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study [published online ahead of print April 6, 2016]. Ann Oncol. doi: 10.1093/annonc/mdw157.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs